Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Clinical Oncology|January 31, 2025
Recent advances in immunotherapy for cervical cancerAiko Ogasawara, Kosei Hasegawa
The Journal of Obstetrics and Gynaecology Research|June 25, 2020
Current and future strategies for treatment of ovarian clear cell carcinomaAiko Ogasawara, Sho Sato, Kosei Hasegawa
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 13, 2024
Premature Classification of Early-stage Endometrioid Ovarian Carcinoma With Mesonephric-like Differentiation as Mesonephric-like AdenocarcinomaYu Miyama, Aiko Ogasawara, Kosei Hasegawa, et al.
Archives of Gynecology and Obstetrics|August 14, 2017
Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancerHiroyuki Yoshida, Daisuke Shintani, Aiko Ogasawara, et al.
The Journal of Obstetrics and Gynaecology Research|May 28, 2015
Sonographic features of congenital infantile fibrosarcoma that appeared as a sacrococcygeal teratoma during pregnancyTakashi Suzuki, Takeshi Murakoshi, Kei Tanaka, et al.
Diagnostic Pathology|November 6, 2019
A unique uterine cervical "teratocarcinosarcoma": a case reportKozue Ito, Mitsutake Yano, Aiko Ogasawara, et al.
Anticancer Research|March 31, 2021
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous CarcinomaMitsutake Yano, Mariko Miyazawa, Naoki Ogane, et al.
Cancer Research and Treatment|July 1, 2020
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS MutationsAiko Ogasawara, Taro Hihara, Daisuke Shintani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2020
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancerDaisuke Shintani, Taro Hihara, Aiko Ogasawara, et al.
Journal of Gynecologic Oncology|August 12, 2024
Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potentialSho Sato, Takahito Miura, Aiko Ogasawara, et al.
Pageof 3